Summary:
Curie.Bio raises $340 million to invest in biotech startups.
Firm aims to revolutionize biotech financing by offering capital and expertise.
Received 4,000 applications since 2022, with a less than 1% acceptance rate.
Plans to invest in 15 to 20 companies this year and up to 25 by 2026.
Curie.Bio Secures Major Funding
Curie.Bio, the biotech accelerator and investment firm founded by Alexis Borisy and Zach Weinberg, has successfully raised $340 million to bolster its investments in innovative startups. This funding marks a significant step in their mission to revolutionize the biotech financing model, providing both capital and expert assistance to founders looking for alternatives to traditional venture capital funding.
A Surge in Applications
Since its inception in 2022, Curie.Bio has garnered an impressive 4,000 applications, showcasing the high demand for its support. The firm has already invested in 26 startups, maintaining a less than 1% acceptance rate, which underscores its selective approach in choosing promising biotech ventures.
Plans for Expansion
With the newly raised capital, Curie.Bio aims to double its investments over the next two years. The organization plans to invest in 15 to 20 biotech companies this year and expand to up to 25 companies by 2026, further solidifying its position in the biotech ecosystem.
Comments